Magnitude and frequency of cytotoxic T-lymphocyte responses: Identification of immunodominant regions of human immunodeficiency virus type 1 subtype C

Journal of Virology

Volumn 76, Issue 20, 2002, Pages 10155-10168

  Novitsky, V ^a   Cao, H ^a   Rybak, N ^a   Gilbert, P ^a   McLane, M F ^a   Gaolekwe, S ^a   Peter, T ^a   Thior, I ^a   Ndung'u, T ^a   Marlink, R ^a   Lee, T H ^a   Essex, M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VPR PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BOTSWANA; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIRUS LOAD;

AMINO ACID SEQUENCE; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036784572     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.20.10155-10168.2002     Document Type: Article

References (101)

1. Abebe, A., D. Demissie, J. Goudsmit, M. Brouwer, C. L. Kuiken, G. Pollakis, H. Schuitemaker, A. L. Fontanet, and T. F. Rinke de Wit. 1999. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13:1305-1311.
2. Addo, M. M., M. Altfeld, E. S. Rosenberg, R. L. Eldridge, M. N. Philips, K. Habeeb, A. Khatri, C. Brander, G. K. Robbins, G. P. Mazzara, P. J. Goulder, B. D. Walker, and the HIV Controller Study Collaboration. 2001. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. USA 98:1781-1786.
3. Aldovini, A., and R. A. Young. 1991. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351:479-482.
4. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390.
5. Allen, T. M., T. U. Vogel, D. H. Fuller, B. R. Mothe, S. Steffen, J. E. Boyson, T. Shipley, J. Fuller, T. Hanke, A. Sette, J. D. Altman, B. Moss, A. J. McMichael, and D. I. Watkins. 2000. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164:4968-4978.
6. Almond, N. M., and J. L. Heeney. 1998. AIDS vaccine development in primate models. AIDS 12(Suppl. A):S133-S140.
7. Altfeld, M., M. M. Addo, R. L. Eldridge, X. G. Yu, S. Thomas, A. Khatri, D. Strick, M. N. Phillips, G. B. Cohen, S. A. Islam, S. A. Kalams, C. Brander, P. J. Goulder, E. S. Rosenberg, and B. D. Walker. 2001. Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 167:2743-2752.
8. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H.-L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
9. Barouch, D. H., A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, G. Heidecker, H. C. Perry, M. E. Davies, H. Xie, C. E. Nickerson, T. D. Steenbeke, C. I. Lord, D. C. Montefiori, T. B. Strom, J. W. Shiver, M. G. Lewis, and N. L. Letvin. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97:4192-4197.
10. Barouch, D. H., A. Craiu, S. Santra, M. A. Egan, J. E. Schmitz, M. J. Kuroda, T. M. Fu, J. H. Nam, L. S. Wyatt, M. A. Lifton, G. R. Krivulka, C. E. Nickerson, C. I. Lord, B. Moss, M. G. Lewis, V. M. Hirsch, J. W. Shiver, and N. L. Letvin. 2001. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 75:2462-2467.
11. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, D. C. Montefiori, M. G. Lewis, S. M. Wolinsky, and N. L. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335-339.
12. Barouch, D. H., S. Santra, M. J. Kuroda, J. E. Schmitz, R. Plishka, A. Buckler-White, A. E. Gaitan, R. Zin, J. H. Nam, L. S. Wyatt, M. A. Lifton, C. E. Nickerson, B. Moss, D. C. Montefiori, V. M. Hirsch, and N. L. Letvin. 2001. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75:5151-5158.
13. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A. Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S. Gelman, D. C. Montefiori, and M. G. Lewis. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486-492.
14. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:8264-8272.
15. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. Set. B 57:289-300.
16. Bergmann, C. C., Q. Yao, C. K. Ho, and S. L. Buckwold. 1996. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J. Immunol. 157:3242-3249.
17. Berzofsky, J. A. 1988. Immunodominance in T lymphocyte recognition. Immunol. Lett. 18:83-92.
18. Betts, M. R., J. Krowka, C. Santamaria, K. Balsamo, F. Gao, G. Mulundu, C. Luo, N. N'Gandu, H. Sheppard, B. H. Hahn, S. Allen, and J. A. Frelinger. 1997. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J. Virol. 71: 8908-8911.
19. Björnal, Å., A. Sönnerborg, C. Tschering, J. Albert, and E. M. Fenyö. 1999. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res. Hum. Retroviruses 15:647-653.
20. Buseyne, F., M. McChesney, F. Porrot, S. Kovarik, B. Guy, and Y. Riviere. 1993. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J. Virol. 67:694-702.
21. Calef, C., R. Thakallapally, D. Lang, C. Brander, P. Goulder, O. Yang, and B. Korber. 2000. PeptGen: designing peptides for immunological studies and application to HIV consensus sequences, p. 1-63-I-100. In B. Korber, C. Brander, B. Haynes, R. Koup, C. Kuiken, J. Moore, B. Walker, and D. Watkins (ed.), HIV molecular immunology 2000. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
22. Cao, H., P. Kanki, J. L. Sankale, A. Dieng-Sarr, G. P. Mazzara, S. A. Kalams, B. Korber, S. Mboup, and B. D. Walker. 1997. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J. Virol. 71:8615-8623.
23. Cao, H., I. Mani, R. Vincent, R. Mugerwa, P. Mugyenyi, P. Kanki, J. Ellner, and B. D. Walker. 2000. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J. Infect. Dis. 182:1350-1356.
24. Choudhury, S., M. A. Montano, C. Womack, J. T. Blackard, J. K. Maniar, D. G. Saple, S. Tripathy, S. Sahni, S. Shah, G. P. Babu, and M. Essex. 2000. Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. J. Hum. Virol. 3:35-43.
25. Colmenero, P., P. Berglund, T. Kambayashi, P. Biberfeld, P. Liljestrom, and M. Jondal. 2001. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther. 8:1307-1314.
26. Crotzer, V. L., R. E. Christian, J. M. Brooks, J. Shabanowitz, R. E. Settlage, J. A. Marto, F. M. White, A. B. Rickinson, D. F. Hunt, and V. H. Engelhard. 2000. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J. Immunol. 164:6120-6129.
27. Culmann-Penciolelli, B., S. Lamhamedi-Cherradi, I. Couillin, N. Guegan, J. P. Levy, J. G. Guillet, and E. Gomard. 1994. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J. Virol. 68:7336-7343.
28. Da Silva, J., and A. L. Hughes. 1998. Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). Mol. Biol. Evol. 15:1259-1268.
29. Di Fabio, S., D. Medaglini, C. M. Rush, F. Corrias, G. L. Panzini, M. Pace, P. Verani, G. Pozzi, and F. Titti. 1998. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine 16:485-492.
30. Dorrell, L., T. Dong, G. S. Ogg, S. Lister, S. McAdam, T. Rostron, C. Conlon, A. J. McMichael, and S. L. Rowland-Jones. 1999. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J. Virol. 73:1708-1714.
31. Durali, D., J. Morvan, F. Letourneur, D. Schmitt, N. Guegan, M. Dalod, S. Saragosti, D. Sicard, J. P. Levy, and E. Gomard. 1998. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J. Virol. 72:3547-3553.
32. Esparza, J., and N. Bhamarapravati. 2000. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 355:2061-2066.
33. Evans, D. T., D. H. O'Connor, P. Jing, J. L. Dzuris, J. Sidney, J. da Silva, T. M. Allen, H. Horton, J. E. Venham, R. A. Rudersdorf, T. Vogel, C. D. Pauza, R. E. Bontrop, R. DeMars, A. Sette, A. L. Hughes, and D. I. Watkins. 1999. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5:1270-1276.
34. Evans, T. G., M. C. Keefer, K. J. Weinhold, M. Wolff, D. Montefiori, G. J. Gorse, B. S. Graham, M. J. McElrath, M. L. Clements-Mann, M. J. Mulligan, P. Fast, M. C. Walker, J. L. Excler, A. M. Duliege, and J. Tartaglia. 1999. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180:290-298.
35. Felsenstein, J. 1993. PHYLIP: phylogeny inference package, 3.52c ed. University of Washington, Seattle.
36. Felsenstein, J. 1996. PHYLIP: phylogeny inference package, 3.572c ed. University of Washington, Seattle.
37. Friedman, R. S., F. R. Frankel, Z. Xu, and J. Lieberman. 2000. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J. Virol. 74:9987-9993.
38. Gallimore, A., H. Hengartner, and R. Zinkernagel. 1998. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunol Rev. 164:29-36.
39. Gao, F., D. L. Robertson, C. D. Carruthers, S. G. Morrison, B. Jian, Y. Chen, F. Barre-Sinoussi, M. Girard, A. Srinivasan, A. G. Abimiku, G. M. Shaw, P. M. Sharp, and B. H. Hahn. 1998. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 72:5680-5698.
40. Gonzalo, R. M., D. Rodriguez, A. Garcia-Sastre, J. R. Rodriguez, P. Palese, and M. Esteban. 1999. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17:887-892.
41. Goulder, P. J., M. M. Addo, M. A. Altfeld, E. S. Rosenberg, Y. Tang, U. Govender, N. Mngqundaniso, K. Annamalai, T. U. Vogel, M. Hammond, M. Bunce, H. M. Coovadia, and B. D. Walker. 2001. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by Elispot and intracellular cytokine staining assays. J. Virol. 75:1339-1347.
42. Goulder, P. J., C. Brander, K. Annamalai, N. Mngqundaniso, U. Govender, Y. Tang, S. He, K. E. Hartman, C. A. O'Callaghan, G. S. Ogg, M. A. Altfeld, E. S. Rosenberg, H. Cao, S. A. Kalams, M. Hammond, M. Bunce, S. I. Pelton, S. A. Burchett, K. McIntosh, H. M. Coovadia, and B. D. Walker. 2000. Differential narrow focusing of immunodominant human immunodeficiency virus Gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J. Virol. 74:5679-5690.
43. Graham, B. S. 2000. Clinical trials of HIV vaccines, p. 82-105. In C. Kuiken, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. W. Mellors, J. Mullins, S. Wolinsky, and B. Korber (ed.), HIV sequence compendium 2000. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
44. Hanke, T., and A. J. McMichael. 2000. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6:951-955.
45. Hanke, T., V. C. Neumann, T. J. Blanchard, P. Sweeney, A. V. Hill, G. L. Smith, and A. McMichael. 1999. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17:589-596.
46. Honda, M., K. Matsuo, T. Nakasone, Y. Okamoto, H. Yoshizaki, K. Kitamura, W. Sugiura, K. Watanabe, Y. Fukushima, S. Haga, Y. Katsura, H. Tasaka, K. Komuro, T. Yamada, T. Asano, A. Yamazak, and S. Yamazaki. 1995. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA 92:10693-10697.
47. Hone, D. M., S. Wu, R. J. Powell, D. W. Pascual, J. Van Cott, J. McGhee, T. R. Fouts, R. G. Tuskan, and G. K. Lewis. 1996. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J. Biotechnol. 44:203-207.
48. Iwasaki, A., B. J. Stiernholm, A. K. Chan, N. L. Berinstein, and B. H. Barber. 1997. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158: 4591-4601.
49. Johnston, M. I. 2000. The role of nonhuman primate models in AIDS vaccine development. Mol. Med. Today 6:267-270.
50. Kageyama, S., T. J. Tsomides, Y. Sykulev, and H. N. Eisen. 1995. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J. Immunol. 154:567-576.
51. Kelleher, A. D., C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, C. Brander, G. Ogg, J. S. Sullivan, W. Dyer, I. Jones, A. J. McMichael, S. Rowland-Jones, and R. E. Phillips. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-386.
52. Khan, C. M., B. Villarreal-Ramos, R. J. Pierce, R. Demarco de Hormaeche, H. McNeill, T. Ali, S. Chatfield, A. Capron, G. Dougan, and C. E. Hormaeche. 1994. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. J. Immunol. 153:5634-5642.
53. Korber, B., C. Brander, B. Haynes, R. Koup, C. Kuiken, J. P. Moore, B. D. Walker, and D. I. Watkins (ed.). 2000. HIV molecular immunology 2000. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
54. Korber, B. T., B. T. Foley, C. L. Kuiken, S. K. Pillai, and J. G. Sodroski. 1998. Numbering positions in HIV relative to HXB2CG, p. III-102-III-111. In B. Korber, C. Kuiken, B. Foley, B. Hahn, F. McCutchan, J. Mellors, and J. Sodroski (ed.), Human retroviruses and AIDS 1998. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
55. Lagranderie, M., A. M. Balazuc, B. Gicquel, and M. Gheorghiu. 1997. Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus Nef induces local and systemic cytotoxic T-lymphocyte responses in mice. J. Virol. 71:2303-2309.
56. Lagranderie, M., N. Winter, A. M. Balazuc, B. Gicquel, and M. Gheorghiu. 1998. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses 14:1625-1633.
57. Lim, E. M., M. Lagranderie, R. Le Grand, J. Rauzier, M. Gheorghiu, B. Gicquel, and N. Winter. 1997. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res. Hum. Retroviruses 13:1573-1581.
58. Lippolis, J. D., L. M. Mylin, D. T. Simmons, and S. S. Tevethia. 1995. Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J. Virol. 69:3134-3146.
59. Livingston, B. D., M. Newman, C. Crimi, D. McKinney, R. Chesnut, and A. Sette. 2001. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19:4652-4660.
60. Lo-Man, R., P. Martineau, M. Hofnung, and C. Leclerc. 1993. Induction of T cell responses by chimeric bacterial proteins expressing several copies of a viral T cell epitope. Eur. J. Immunol. 23:2998-3002.
61. Mashishi, T., S. Loubser, W. Hide, G. Hunt, L. Morris, G. Ramjee, S. Abdool-Karim, C. Williamson, and C. M. Gray. 2001. Conserved domains of subtype C Nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res. Hum. Retroviruses 17:1681-1687.
62. Mata, M., and Y. Paterson. 1999. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J. Immunol. 163:1449-1456.
63. McAdam, S., P. Kaleebu, P. Krausa, P. Goulder, N. French, B. Collin, T. Blanchard, J. Whitworth, A. McMichael, and F. Gotch. 1998. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 12:571-579.
64. McGettigan, J. P., H. D. Foley, I. M. Belyakov, J. A. Berzofsky, R. J. Pomerantz, and M. J. Schnell. 2001. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J. Virol. 75:4430-4434.
65. Nathanson, N., V. M. Hirsch, and B. J. Mathieson. 1999. The role of nonhuman primates in the development of an AIDS vaccine. AIDS 13 (Suppl. A):S113-S120.
66. Ndung'u, T., B. Renjifo, and M. Essex. 2001. Construction and analysis of an infectious human immunodeficiency virus type 1 subtype C molecular clone. J. Virol. 75:4964-4972.
67. Ndung'u, T., B. Renjifo, V. A. Novitsky, M. F. McLane, S. Gaolekwe, and M. Essex. 2000. Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. Virology 278:390-399.
68. Neilson, J. R., G. C. John, J. K. Carr, P. Lewis, J. K. Kreiss, S. Jackson, R. W. Nduati, D. Mbori-Ngacha, D. D. Panteleeff, S. Bodrug, C. Giachetti, M. A. Bott, B. A. Richardson, J. Bwayo, J. Ndinya-Achola, and J. Overbaugh. 1999. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J. Virol. 73:4393-4403.
69. Novitsky, V., P. O. Flores-Villanueva, P. Chigwedere, S. Gaolekwe, H. Bussman, G. Sebetso, R. Marlink, E. J. Yunis, and M. Essex. 2001. Identification of most frequent HLA class 1 antigen specificities in Botswana: relevance for HIV vaccine design. Hum. Immunol. 62:146-156.
70. Novitsky, V., N. Rybak, M. F. McLane, P. Gilbert, P. Chigwedere, I. Klein, S. Gaolekwe, S. Y. Chang, T. Peter, I. Thior, T. Ndung'u, F. Vannberg, B. T. Foley, R. Marlink, T. H. Lee, and M. Essex. 2001. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific Elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J. Virol. 75:9210-9228.
71. Novitsky, V., U. R. Smith, P. Gilbert, M. F. McLane, P. Chigwedere, C. Williamson, T. Ndung'u, I. Klein, S. Y. Chang, T. Peter, I. Thior, B. T. Foley, S. Gaolekwe, N. Rybak, S. Gaseitsiwe, F. Vannberg, R. Marlink, T. H. Lee, and M. Essex. 2002. HIV-1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J. Virol. 76:5435-5451.
72. Novitsky, V. A., M. A. Montano, M. F. McLane, B. Renjifo, F. Vannberg, B. T. Foley, T. P. Ndung'u, M. Rahman, M. Makhema, J., R. Marlink; and M. Essex. 1999. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. J. Virol. 73:4427-4432.
73. Oggioni, M. R., D. Medaglini, L. Romano, F. Peruzzi, T. Maggi, L. Lozzi, L. Bracci, M. Zazzi, F. Manca, P. E. Valensin, and G. Pozzi. 1999. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. AIDS Res. Hum. Retroviruses 15:451-459.
74. Oscherwitz, J., F. M. Gotch, K. B. Cease, and J. A. Berzofsky. 1999. New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design. AIDS 13(Suppl. A):S163-S174.
75. Oscherwitz, J., M. E. Zeigler, T. E. Gribbin, and K. B. Cease. 1999. A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. Vaccine 17:2392-2399.
76. Osmanov, S., C. Pattou, N. Walker, B. Schwardlander, and J. Esparza. 2002. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 29:184-190.
77. Pal, R., D. Venzon, N. L. Letvin, S. Santra, D. C. Montefiori, N. R. Miller, E. Tryniszewska, M. G. Lewis, T. C. VanCott, V. Hirsch, R. Woodward, A. Gibson, M. Grace, E. Dobratz, P. D. Markham, Z. Hel, J. Nacsa, M. Klein, J. Tartaglia, and G. Franchini. 2002. ALVAC-SIV-Gag-Pol-Env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76:292-302.
78. Peeters, M., R. Vincent, J. L. Perret, M. Lasky, D. Patrel, F. Liegeois, V. Courgnaud, R. Seng, T. Matton, S. Molinier, and E. Delaporte. 1999. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:115-121.
79. Peng, B., and M. Robert-Guroff. 2001. Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol. Lett. 78:195-200.
80. Rayevskaya, M. V., and F. R. Frankel. 2001. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol. 75:2786-2791.
81. Renjifo, B., W. Fawzi, D. Mwakagile, D. Hunter, G. Msamanga, D. Spiegelman, M. Garland, C. Kagoma, A. Kim, B. Chaplin, E. Hertzmark, and M. Essex. 2001. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J. Hum. Virol. 4:16-25.
82. Rodenburg, C. M., Y. Li, S. A. Trask, Y. Chen, J. Decker, D. L. Robertson, M. L. Kalish, G. M. Shaw, S. Allen, B. H. Hahn, and F. Gao. 2001. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res. Hum. Retroviruses 17: 161-168.
83. Rowland-Jones, S. L., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi, J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummer. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102:1758-1765.
84. Salminen, M. O., B. Johansson, A. Sonnerborg, S. Ayehunie, D. Gotte, P. Leinikki, D. S. Burke, and F. E. McCutchan. 1996. Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Res. Hum. Retroviruses 12:1329-1339.
85. Seibert, S. A., C. Y. Howell, M. K. Hughes, and A. L. Hughes. 1995. Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). Mol. Biol. Evol. 12:803-813.
86. Seth, A., I. Ourmanov, M. J. Kuroda, J. E. Schmitz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin. 1998. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc. Natl. Acad. Sci. USA 95:10112-10116.
87. Seth, A., I. Ourmanov, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, L. Wyatt, M. Carroll, B. Moss, D. Venzon, N. L. Letvin, and V. M. Hirsch. 2000. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74:2502-2509.
88. Shastri, N., T. Serwold, and F. Gonzalez. 1995. Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J. Immunol. 155:4339-4346.
89. + T cells and antiviral protective immunity. J. Virol. 75:9665-9670.
90. Shata, M. T., M. S. J. Reitz, A. L. DeVico, G. K. Lewis, and D. M. Hone. 2001. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20:623-629.
91. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
92. Tscherning, C., A. Alaeus, R. Fredriksson, A. Bjorndal, H. Deng, D. R. Littman, E. M. Fenyo, and J. Albert. 1998. Differences in chemokine co-receptor usage between genetic subtypes of HIV-1. Virology 241:181-188.
93. UNAIDS. 2001, posting date. AIDS epidemic update. December 2001. [On-line.] http: //www.unaids.org/worldaidsday/2001/Epiupdate2001/Epiupdate2001_en.pdf. UNAIDS.
94. UNAIDS and W. H. O. 2000, posting date. Global HIV/AIDS & STD surveillance. Epidemiological fact sheets by country. [Online.] http://www .who.int/emc-hiv/fact_sheets/
95. van Harmelen, J., C. Williamson, B. Kim, L. Morris, J. Carr, S. S. Abdool Karim, and F. McCutchan. 2001. Characterization of full length HIV-1 subtype C sequences from South Africa. AIDS Res. Hum. Retroviruses 17:1527-1531.
96. Wherry, E. J., K. A. Puorro, A. Porgador, and L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163:3735-3745.
97. Wilson, S. E., S. L. Pedersen, J. C. Kunich, V. L. Wilkins, D. L. Mann, G. P. Mazzara, J. Tartaglia, C. L. Celum, and H. W. Sheppard. 1998. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res. Hum. Retroviruses 14:925-937.
98. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51-88.
99. Yu, X. G., H. Shang, M. M. Addo, R. L. Eldridge, M. N. Phillips, M. E. Feeney, D. Strick, C. Brander, P. J. Goulder, E. S. Rosenberg, B. D. Walker, and M. Altfeld, 2002. Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses. AIDS 16:321-328.
100. Zhang, C., J. L. Cornette, J. A. Berzofsky, and C. DeLisi. 1997. The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. Vaccine 15:1291-1302.
101. Zheng, B., F. L. Graham, D. C. Johnson, T. Hanke, M. R. McDermott, and L. Prevec. 1993. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 11:1191-1198.